Genetic polymorphisms in assessing interindividual variability in delivered dose.
about
Assessing biomarker use in risk assessment - A survey of practitionersConsiderations for using genetic and epigenetic information in occupational health risk assessment and standard settingWarfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleedingIncorporation of pharmacokinetic and pharmacodynamic data into risk assessments.Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding riskWarfarin therapy: in need of improvement after all these years.Reconstructing population exposures to environmental chemicals from biomarkers: challenges and opportunities.Human health effects of dichloromethane: key findings and scientific issuesGenetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers.Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?Modeling the Human Kinetic Adjustment Factor for Inhaled Volatile Organic Chemicals: Whole Population Approach versus Distinct Subpopulation ApproachPharmacogenomic effect of cytochrome P450 2C9 polymorphisms in different populations.Dispelling urban myths about default uncertainty factors in chemical risk assessment--sufficient protection against mixture effects?Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics.The influence of genetic polymorphisms on population variability in six xenobiotic-metabolizing enzymes.Genetic Polymorphism in Glutathione Transferases (GST): Population distribution of GSTM1, T1, and P1 conjugating activity.Genetic polymorphism in paraoxonase 1 (PON1): Population distribution of PON1 activity.Role of metabolism in parathion-induced hepatotoxicity and immunotoxicity.Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity.Physiologically based pharmacokinetic model use in risk assessment--Why being published is not enough.Assessing human variability in kinetics for exposures to multiple environmental chemicals: a physiologically based pharmacokinetic modeling case study with dichloromethane, benzene, toluene, ethylbenzene, and m-xylene.Oxidative stress induced in the workers of natural gas refineries, no role for GSTM1 and GSTT1 polymorphisms.
P2860
Q23909906-3796E855-EEE9-4944-AF41-C2832B738AA5Q23919015-0FE36202-2808-48E7-9F33-FDEF1618CD41Q24647605-61409283-41D6-4D7D-B555-E6B82117525DQ33519666-701425F5-BE40-46EC-B582-D924BDCFE07BQ33617751-F7758E7C-DD41-4D9E-A27E-55DFA632A16AQ33793086-10EE7CB8-F406-4B2B-86FC-642E0B251237Q34746222-984600E6-E3DF-4228-AB67-85C7041F361CQ35039376-74FFCD51-12FF-44D3-80BB-884140358890Q35753607-74A6244C-F2E8-423B-B107-BC7E6F47A9DBQ35826999-6F69985E-6099-4692-AD01-C4412AB9B250Q35864881-651AB654-DB97-4906-AC25-660548809A63Q36481564-494D5AED-B14E-4E28-A946-B872E3F9B1C5Q37004073-872A0D3B-1165-435E-94D0-281FAE7EBF6FQ37264555-55A237D1-A6E6-4F24-8390-5C167E5ECCA2Q37698404-291B4883-04D3-4CA5-BABC-D72343118067Q37698411-BE155BB2-DB89-4EB0-985A-FB25366CB408Q37698417-457CBA59-C6AF-4B36-93E2-FCDE8B573ADFQ38512059-FE757A89-AC79-4350-9B29-667C40F87EB8Q46202438-B39F6071-D069-415D-9FA6-D9F60107162BQ53399970-42DBCDC2-5167-47CE-A499-1D4986AF544DQ53573948-79DB3B57-E4A9-4796-8AE7-92A9A20A6683Q54303394-ED592305-1945-4A7F-AB80-3DB18BBD4C73
P2860
Genetic polymorphisms in assessing interindividual variability in delivered dose.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Genetic polymorphisms in assessing interindividual variability in delivered dose.
@ast
Genetic polymorphisms in assessing interindividual variability in delivered dose.
@en
Genetic polymorphisms in assessing interindividual variability in delivered dose.
@nl
type
label
Genetic polymorphisms in assessing interindividual variability in delivered dose.
@ast
Genetic polymorphisms in assessing interindividual variability in delivered dose.
@en
Genetic polymorphisms in assessing interindividual variability in delivered dose.
@nl
prefLabel
Genetic polymorphisms in assessing interindividual variability in delivered dose.
@ast
Genetic polymorphisms in assessing interindividual variability in delivered dose.
@en
Genetic polymorphisms in assessing interindividual variability in delivered dose.
@nl
P2093
P356
P1476
Genetic polymorphisms in assessing interindividual variability in delivered dose.
@en
P2093
P304
P356
10.1006/RTPH.2001.1517
P407
P433
P577
2002-04-01T00:00:00Z